| Literature DB >> 35261619 |
Zhihui Liang1,2, Xin Wang1,2, Ge Yu1,2, Min Li1,2, Shuting Shi1,2, Hang Bao3, Chen Chen3, Duo Fu1,3, Wei Ma1, Changying Xue3, Bingbing Sun1,2.
Abstract
Aluminum oxyhydroxide (AlOOH) adjuvants are widely used in human vaccines. However, the interaction mechanisms at the material-bio interface, and further understandings on physicochemical property-dependent modulation of the immune responses still remain uncertain. Herein, a library of AlOOH nanorods with well-defined aspect ratios is designed to explore the mechanisms of adjuvanticity. The aspect ratios of AlOOH nanorods were demonstrated to be intrinsically modulated by the hydroxide supersaturation level during crystal growth, leading to the differences in surface free energy (SFE). As a result, higher aspect ratio AlOOH nanoadjuvants with lower SFE exhibited more hydrophobic surface, resulting in more membrane depolarization, cellular uptake and dendritic cell (DC) activation. By using hepatitis B surface antigen (HBsAg) virus-like particles (VLPs) or SARS-CoV-2 spike protein receptor-binding domain (RBD) as model antigens, AlOOH nanorods with higher aspect ratio were determined to elicit more potent humoral immune responses, which could be attributed to the enhanced DC activation and the efficient antigen trafficking to the draining lymph nodes. Our findings highlight the critical role of aspect ratio of AlOOH nanorods in modulating adjuvanticity, and further provide a design strategy for engineered nanoadjuvants for prophylactic vaccines.Entities:
Keywords: Adjuvants; Aluminum oxyhydroxide; Hepatitis B surface antigen; Humoral immune response; SARS-CoV-2 RBD; Surface hydrophobicity
Year: 2022 PMID: 35261619 PMCID: PMC8896059 DOI: 10.1016/j.nantod.2022.101445
Source DB: PubMed Journal: Nano Today ISSN: 1748-0132 Impact factor: 18.962
Scheme 1Schematic illustration of aspect ratio-dependent nano-bio interaction and potent humoral immune response induction by AlOOH nanorods.
Fig. 1Schematic illustration of the synthetic chemistry and TEM analysis of AlOOH nanorods. (a) Schematic representation of the crystal growth of AlOOH nanorods under acidic conditions via a hydrothermal method. (b) Representative TEM images and (c) length distribution analysis of AlOOH nanorods prepared with initial pH at 4.0, 5.0, and 6.0, respectively. They were noted as Rod 1, Rod 2, and Rod 3. All synthesis of engineered AlOOH nanorods were conducted at 160 °C for 16 h. At least 150 nanorods were randomly selected to determine the length distribution. Alhydrogel® adjuvant was used as a control.
The aspect ratios, hydrodynamic sizes and zeta potentials of AlOOH nanorods and Alhydrogel® in water.
| Sample ID | Length (nm) | Aspect Ratio | Hydrodynamic Size in Water (nm) | Zeta Potential in Water (mV) |
|---|---|---|---|---|
| Rod 1 | 342 ± 98 | 51 ± 14 | 271 ± 3 | 44 ± 1 |
| Rod 2 | 277 ± 43 | 23 ± 5 | 254 ± 8 | 55 ± 1 |
| Rod 3 | 47 ± 11 | 7 ± 2 | 125 ± 2 | 51 ± 2 |
| Alhydrogel® | 41 ± 7 | 6 ± 1 | 503 ± 9 | 27 ± 2 |
Fig. 2XRD and hydrophobicity analysis of AlOOH nanorods. (a) XRD patterns and (b) surface free energy of AlOOH nanorods. (c) Relative hydrophobicity was determined by adsorption of Rose Bengal (40 μg/mL) on AlOOH nanorods (0–1.2 mg/mL). Alhydrogel® was used as a control. (d) Schematic diagram of the crystal growth of AlOOH nanorods under the hydrothermal conditions. *p < 0.05 and **p < 0.01.
Fig. 3Cell membrane depolarization induced by AlOOH nanorods and subsequent cellular uptake and activation of bone marrow-derived dendritic cell (BMDCs). (a) Cell membrane depolarization was determined by DiBAC4(3). BMDCs were pre-treated with DiBAC4(3) for 30 min before incubating with AlOOH nanorods (250 μg/mL). The real-time monitoring of fluorescence intensity was performed at 37 °C for 2 h. (b) QCM-D determination of the interaction of AlOOH nanorods (250 μg/mL) with cell membrane mimics, the DMPA lipid bilayers, on silica coated quartz crystal sensors. The deposition kinetics were measured at a flow rate of 120 μL/min. Data were recorded from the moment of the actual arrival of nanorods to the sensor. (c) Confocal microscopy images of AlOOH nanorod-treated BMDCs. Cells were exposed to FITC-labeled AlOOH nanorods (20 μg Al/mL) for 4 h in the presence of 10 ng/mL of GM-CSF. The cell membrane and cell nuclei were stained with WGA Alexa Fluor® 594 conjugate (red) and Hoechst 33342 (blue), respectively. The scale bar is 10 µm. (d) Flow cytometry analysis of cellular uptake levels in BMDCs. After exposure to FITC-labeled AlOOH nanorods at a dose of 100 μg Al/mL for 12 h, cells were collected and washed by DPBS for analysis. (e) AlOOH nanorods mediated antigen uptake by BMDCs. The nanoparticles were pre-adsorbed with FITC-labeled RBD antigen and then incubated with BMDCs for 12 h. Cells were collected and washed for flow cytometry analysis to determine the FITC fluorescence intensity. (f-g) BMDC maturation induced by AlOOH nanorods. (f) CD80 and (g) CD86 on CD11c+ cells were determined by flow cytometry after incubation with nanoparticles at 37 °C for 12 h. The results were shown as the fold-increase in mean fluorescence intensity. (h-i) Cytokine production induced by AlOOH nanorods in BMDCs. BMDCs were exposed to nanorods (500 μg/mL) for 24 h. (h) IL-1β and (i) IL-6 productions were determined by ELISA. *p < 0.05 and **p < 0.01 compared to control; #p < 0.05 and ##p < 001 compared to Rod 1-treated cells; @p < 0.05 compared to Alhydrogel-treated cells. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 4AlOOH nanorods enhanced humoral immune responses and antigen retention in HBsAg vaccination model. (a) Vaccination procedure. 6-week female C57BL/6 mice (n = 6) were vaccinated with HBsAg/AlOOH (2 μg/50 μg Al) intramuscularly (i.m.) on day 0 and day 21. Saline-, HBsAg- and Alhydrogel-immunized mice were used as controls. Serum HBsAg-specific (b) total IgG and (c) IgG1 titers on day 42. *p < 0.05 and **p < 0.01 compared to saline buffer-treated mice; #p < 0.05 and #p < 0.01 compared to HBsAg-treated mice; @p < 0.05 and @@p < 0.01 compared to HBsAg/Rod 1-immunized mice. (d-e) HBsAg retention at injection sites. AlOOH nanorods were pre-adsorbed with Alexa Flour™ 700-labeled HBsAg. C57BL/6 mice were immunized with different vaccine formulations containing 10 μg of HBsAg and 250 μg of Al by intramuscular administration. The fluorescence intensity at Ex 702/Em 723 nm was recorded by an IVIS optical imaging system (NightOWL II LB 983, Berthold) at the indicated time points (0–96 h). IndiGo software was used to quantify the mean fluorescence intensity (MFI) at the injection sites, and the data were normalized by the initial fluorescence intensity. *p < 0.05 and **p < 0.01 compared to HBsAg-treated mice; #p < 0.05 compared to HBsAg/Alhydrogel-immunized mice.
Fig. 5Potent humoral immune responses to SARS-CoV-2 RBD vaccination and the activation of DCs in lymph nodes. (a) Vaccination procedure. 6-week female BALB/c mice (n = 6) were immunized with RBD/AlOOH (10 μg/50 μg Al) intramuscularly on day 0 and day 21. RBD- and saline-immunized mice were used as controls. Serum RBD-specific (b) total IgG and (c) IgG1 titers on day 42. *p < 0.05 and **p < 0.01 compared to saline-immunized mice; #p < 0.05 and #p < 0.01 compared to RBD-immunized mice; @p < 0.05 compared to RBD/Rod 1-immunized mice. (d) Biocompatibility evaluations of vital organ sections in RBD vaccination model by H&E staining. The scale bar is 40 µm. (e-g) The translocation of RBD and the activation of DCs in draining lymph nodes (dLNs) after treated with indicated vaccine formulations for 48 h in CD-1 mice. (e) The percentage of RBD-containing DCs within dLNs. RBD was labeled by FITC and determined by flow cytometry. The expression of (f) MHC class II molecule and (g) CD80 on the surface of DCs in inguinal lymph nodes. *p < 0.05, **p < 0.01 and ***p < 0.001 compared to RBD-treated mice; #p < 0.05, ##p < 0.01 and ###p < 0.001 compared to RBD/Rod 1-treated mice.